Abraxis Health Dedicates State of the Art Nanotechnology & Biologics Facility in Phoenix, Arizona

-Flagship Facility Compliant with Worldwide Nanobiologics Regulatory
Requirements-
LOS ANGELES--(Business Wire)--
Abraxis Health, a fully-integrated personalized healthcare division of Abraxis
BioScience, Inc. (NASDAQ:ABII), today announced the dedication of its new
manufacturing facility in Phoenix, Arizona. The state of the art biopharma
manufacturing plant represents a $70 million investment by LA-based Abraxis, and
will create up to 200 high tech jobs. The new facility will manufacture
ABRAXANE®, the first solvent-free chemotherapy treatment option for metastatic
breast cancer, which was developed using Abraxis BioScience's proprietary nab®
technology platform. The company now has multiple agreements in place for the
development of novel, insoluble compounds using the nanobiologics technology
employed at the Phoenix plant.

The facility will be the world`s largest and most sophisticated protein
nanobiologics manufacturing plant, with annual production capacity of over 10
million units, and the capability to expand to 20 million units, suitable for
worldwide distribution. The site, formerly owned by Watson Pharmaceuticals, was
purchased by Abraxis in July 2007. Abraxis has hired more than 100 former Watson
employees, recruited additional staff from among the local skilled workforce,
and will continue to recruit as the facility ramps up production.

"The outlook for Abraxis is immensely encouraging," said founder and Chairman
Dr. Patrick Soon-Shiong. "As we continue to grow, these new premises in Phoenix
will become the flagship manufacturing facility for our cutting edge
technology."

State Attorney General Terry Goddard commented, "Arizona is proud to welcome
Abraxis as a powerful new addition to our growing life sciences sector."

"This is great news for Phoenix," said Mayor Phil Gordon. "We are delighted that
Abraxis has chosen our city for this state of the art nanotech manufacturing
plant, bringing highly skilled jobs and a welcome boost for our economy."

State, city and business leaders attended today`s ceremony to dedicate the new
facility, including Attorney General Goddard and Mayor Phil Gordon.

About Abraxis BioScience, Inc.

Abraxis Health, which will operate the Phoenix facility, is a division of
Abraxis Bioscience Inc. Abraxis BioScience is a fully integrated global
biotechnology company dedicated to the discovery, development and delivery of
next-generation therapeutics and core technologies that offer patients safer and
more effective treatments for cancer and other critical illnesses. The company's
portfolio includes the world's first and only protein-bound nanoparticle
chemotherapeutic compound (ABRAXANE®), which is based on the company's
proprietary tumor targeting technology known as the nab® platform. The first FDA
approved product to use this nab platform, ABRAXANE, was launched in 2005 for
the treatment of metastatic breast cancer and is now approved in 38 countries.
The company continues to expand the nab platform through a robust clinical
program and deep product pipeline. Abraxis trades on the NASDAQ Global Market
under the symbol ABII. For more information about the company and its products,
please visit www.abraxisbio.com.

Investors and Media Inquiries:
Abraxis BioScience, Inc.
Maili Bergman, 310-883-1300
investorrelations@abraxisbio.com

Copyright Business Wire 2009